Boston Scientific Corporation $BSX Position Boosted by Parnassus Investments LLC

Parnassus Investments LLC lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 14.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 7,899,240 shares of the medical equipment provider’s stock after buying an additional 1,014,800 shares during the quarter. Boston Scientific accounts for about 1.9% of Parnassus Investments LLC’s holdings, making the stock its 20th biggest holding. Parnassus Investments LLC’s holdings in Boston Scientific were worth $753,193,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of BSX. Norges Bank bought a new position in shares of Boston Scientific during the fourth quarter worth about $2,199,395,000. Egerton Capital UK LLP lifted its position in shares of Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after purchasing an additional 3,671,548 shares during the last quarter. Alphinity Investment Management Pty Ltd bought a new position in shares of Boston Scientific during the fourth quarter worth about $252,918,000. Marshall Wace LLP lifted its position in shares of Boston Scientific by 30.7% during the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock worth $956,680,000 after purchasing an additional 2,301,383 shares during the last quarter. Finally, Credit Agricole S A bought a new position in shares of Boston Scientific during the third quarter worth about $204,812,000. Institutional investors own 89.07% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: BTIG reiterated a bullish view on Boston Scientific, highlighting a low forward P/E and significant upside potential, which may help support the stock after its sharp year-to-date de-rating. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Recent analyst commentary still shows broad Wall Street support, with several buy ratings and price targets well above the current trading range, suggesting some investors see the selloff as overdone.
• Neutral Sentiment: Boston Scientific’s Q1 results beat estimates slightly, with revenue up 11.6% year over year, but the market appears more focused on forward guidance and segment-level growth trends than the last quarter’s results.
• Neutral Sentiment: Erste Group trimmed FY2026 and FY2027 EPS estimates only modestly, signaling little change to the core earnings outlook, though the revisions add to the cautious tone around near-term expectations.
• Negative Sentiment: The stock has been sliding after a guidance reduction and renewed scrutiny over slower growth in important businesses, including WATCHMAN and ablation technologies, which is weighing on investor confidence. Boston Scientific Stock (BSX) Opinions on Recent Stock Decline
• Negative Sentiment: A recent market update showed BSX declined again in the latest session, reinforcing the bearish momentum that has followed the guidance-related selloff. Boston Scientific (BSX) Stock Moves -1.27%: What You Should Know

Insider Buying and Selling at Boston Scientific

In other news, Director David C. Habiger purchased 2,250 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig purchased 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have bought 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on BSX shares. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Robert W. Baird set a $70.00 price target on shares of Boston Scientific in a research report on Thursday, May 28th. Leerink Partners dropped their price objective on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a research note on Thursday, May 28th. Jefferies Financial Group dropped their price objective on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Finally, Raymond James Financial reiterated an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $85.92.

Boston Scientific Price Performance

BSX opened at $47.22 on Friday. The firm has a market cap of $70.18 billion, a price-to-earnings ratio of 19.76, a price-to-earnings-growth ratio of 0.91 and a beta of 0.56. Boston Scientific Corporation has a fifty-two week low of $46.91 and a fifty-two week high of $109.50. The company’s 50-day moving average price is $56.68 and its 200 day moving average price is $75.14. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. Boston Scientific’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has approved a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.